CJD (Creutzfeldt-Jakob disease) drug success "opens doors for diagnostic test":
This article was originally published in Clinica
Executive Summary
The unexpected success of a one-off, highly experimental trial of a drug to halt the progress of Creutzfeldt-Jakob disease (CJD) in a UK patient has "opened the doors to developing a diagnostic test". So said doctors at a meeting held last week in Belfast, Northern Ireland, to discuss the developments. Although more research is needed to confirm the effectiveness of pentosan polysulphate (PPS) in halting or even reversing the neurodegenerative effects of the disease, experts agree that the earliest possible diagnosis is the key to preventing its slow but invariably fatal progression.